RNS14 Dec 2021 07:20
The first half of the financial year saw record performance as prior investment into clinical service lab capacity started to deliver a substantial return, with significant growth seen in both Genomic Technologies and Genomic Services business segments. The Board is confident that trading for the full year will remain robust and that full year revenues are therefore likely to exceed current market expectations, already upgraded previously in October.
Financial highlights
-- Revenues increased by 113% to GBP17.5m (H1 FY21: GBP8.2m) with Genomic Services segment up 260% to GBP10.5m and Genomic Technologies segment up 32% to GBP6.9m